INS and type 2 diabetes mellitus: Besides, some large-scale RCTs such as Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS) (34), The Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) (35), and Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia (ORIGIN) (36) were also excluded due to no reports of body weight change or without significant weight change difference between two arms.